Latest Hudson River Capital News
Mar 2, 2016
In addition to the collaboration, Johnson & Johnson Innovation has participated in WellDoc’s Series B financing round that has raised $29.5 million. 04:20 PM Share LAS VEGAS – WellDoc, a mobile health technology vendor, announced Tuesday at HIMSS16 a collaboration with LifeScan, a blood glucose monitoring business within the Johnson & Johnson Diabetes Care Companies, to deliver a digital health system for patients living with type-2 diabetes. In addition to the collaboration, Johnson & Johnson Innovation/JJDC Inc. participated in WellDoc’s $29.5 million Series B financing. Under the collaboration, WellDoc’s BlueStar product, an FDA-cleared digital therapeutic for adults who live with type-2 diabetes, will be integrated with LifeScan’s OneTouch Verio Flex Bluetooth Smart blood glucose monitoring system and OneTouch Reveal mobile app. The collaboration seeks to leverage LifeScan’s blood glucose monitoring system and mobile app along with the data analytics and patient engagement of WellDoc’s reimbursable mobile prescription therapy to create a real-time, personalized approach to the management of type-2 diabetes. “Together we seek to provide those living with type-2 diabetes a best-in-class diabetes management solution that delivers evidence-based and outcomes-driven support in a consumer-friendly manner,” said Kevin McRaith, CEO of WellDoc. “This is a very significant step forward for our company and has the potential to make a difference in the lives of millions of people living with this chronic disease.” Samsung Ventures, the venture arm of the consumer electronics giant, acted as the lead investor in the initial WellDoc Series B raise with existing investor Merck Global Health Innovation Fund serving as co-lead. Adage Capital Management, Excel Venture Management, Asset Ventures Management, Alexandria Venture Investments, Hudson River Capital Partners LLC and other investors also participated in the financing. WellDoc develops mobile systems to drive behavioral and clinical change in chronic disease with the goal of improving patient self-management and helping physicians overcome gaps in care to improve clinical outcomes and decrease cost. Twitter: @SiwickiHealthIT This story is part of our ongoing coverage of the HIMSS16 conference. Follow our live blog for real-time updates, and visit Destination HIMSS16 for a full rundown of our reporting from the show. For a selection of some of the best social media posts of the show, visit our Trending at #HIMSS16 hub. Share
Hudson River Capital Team
1 Team Member
Hudson River Capital has 1 team member, including former Chief Executive Officer, Daniel T Pickett III.